SEC Filing Form 4

Harvey Robert Klingensmith, a director at Core Laboratories Inc. /DE/, reported a series of transactions on April 1, 2026. In a non-derivative transaction, 8,069 shares of Common Stock were acquired. In derivative transactions, 7,895 Restricted Shares were acquired, and 8,069 Restricted Shares were disposed of. The Restricted Shares acquired are subject to a one-year vesting period ending April 1, 2027, as detailed in footnote F1. The disposed Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026, as per footnote F2. All transactions were reported with a price per share of 0.0.